FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | 本月底法定/註冊股本總額： RMB 103,568,013 備註： 因本公司是於中華人民共和國註冊成立的公司，「法定股本」之概念不適用於本公司，上 ...

Core Viewpoint - Eagle Eye Technology-B (02251) has seen a decline of over 5%, currently trading at HKD 11.51, as the market shifts focus to the 2025 fiscal year performance [1] Financial Performance - For the first half of 2025, Eagle Eye Technology reported a revenue of RMB 83.713 million, representing a year-on-year decrease of 10.7% [1] - The company recorded a net profit of RMB 443,000 [1] - Since its listing, Eagle Eye Technology has consistently operated at a loss, with cumulative annual losses amounting to RMB 594 million from 2022 to 2024 [1]

Core Viewpoint - Eagle Vision Technology-B (02251) has seen a decline of over 5%, currently trading at HKD 11.51, as market attention shifts towards the company's performance for the fiscal year 2025 [1] Financial Performance - For the first half of 2025, Eagle Vision Technology reported a revenue of RMB 83.713 million, representing a year-on-year decrease of 10.7% [1] - The company recorded a net profit of RMB 443,000 for the same period [1] - Since its listing, Eagle Vision Technology has consistently operated at a loss, with cumulative annual losses amounting to RMB 594 million from 2022 to 2024 [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京鷹瞳科技發展股份有限公司 (「本公司」) (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103, ...

Group 1 - The company, Eagle Vision Technology-B (02251), announced a share buyback plan, spending approximately HKD 157.4 million to repurchase 13,500 shares by December 30, 2025 [1]

公司名稱： 北京鷹瞳科技發展股份有限公司(「本公司」) (於中華人民共和國註冊成立的股份有限责任公司) 呈交日期： 2025年12月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 第 2 頁 共 7 頁 v 1.3.0 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | - ...

Group 1 - The company, Eagle Vision Technology-B (02251), announced a share buyback on December 29, 2025, spending HKD 205,100 to repurchase 17,200 shares [1] - The buyback price per share ranged from HKD 11.87 to HKD 11.95 [1]

Group 1 - The company, Eagle Vision Technology-B (02251), announced a share buyback plan [1] - The total amount spent on the buyback is HKD 205,100 [1] - The company repurchased 17,200 shares at a price range of HKD 11.87 to HKD 11.95 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京鷹瞳科技發展股份有限公司(「本公司」) (於中華人民共和國註冊成立的股份有限责任公司) 呈交日期： 2025年12月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | ...

Group 1 - The "Qihang·2025 Financial Summit" was successfully held on December 26 in Beijing, focusing on the theme "New Starting Point, New Momentum, New Journey," gathering hundreds of leaders and guests from regulatory bodies, industry associations, financial institutions, listed companies, and media [1] - The 14th "Jinzhi Award" results were announced, with Airdoc winning the title of "Outstanding Frontier Technology Enterprise," highlighting its recognition in the field of innovative technology [1][3] - The "Jinzhi Award" aims to establish benchmarks for high-quality development, guiding listed companies to focus on their core businesses, continue innovation, and fulfill social responsibilities, thereby promoting capital concentration towards quality enterprises [3] Group 2 - Airdoc, founded in 2015, is dedicated to providing comprehensive AI solutions for chronic disease early screening and management, myopia prevention, stress monitoring, and amblyopia treatment, positioning itself as a leader in the global retinal imaging AI field [4] - Airdoc became the first company in China to obtain NMPA registration for Class III AI-assisted diagnostic medical devices for retinal imaging, marking a significant achievement in the medical AI sector [4] - As of now, Airdoc's AI retinal imaging products have provided disease auxiliary diagnosis and health risk assessment for 30 million people, showcasing its impact in the healthcare industry [4]